StockNews.AI
SIGA
StockNews.AI
21 days

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

1. SIGA announces conference call for business update on August 5, 2025. 2. CEO Diem Nguyen and CFO Daniel Luckshire will provide insights during the call. 3. The company focuses on developing medicines for infectious diseases, especially orthopoxviruses. 4. TPOXX® is approved in the U.S. for smallpox treatment and authorized elsewhere. 5. A replay of the call will be available, emphasizing transparency to investors.

4m saved
Insight
Article

FAQ

Why Bullish?

The business update may reveal positive developments, boosting investor confidence. Historical trends show stock typically rises post-updates.

How important is it?

The upcoming update could significantly influence stock sentiment and trading activity, making it relevant.

Why Short Term?

The conference call's immediate effects are typically seen in the days following the event. Previous updates have led to short-term price fluctuations.

Related Companies

MRNANVAXBNTX
July 29, 2025 07:30 ET  | Source: SIGA Technologies Inc. NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com. Contacts:Suzanne Harnettsharnett@siga.com and

Related News